Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 11/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 8/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 8/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9603823 | 0.97 | DPP4 (0.44) | DPP4ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL14336163 | 0.94 | DPP4 (0.45) | DPP4ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL12955380 | 0.91 | DPP4 (0.42) | DPP4ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL28899291 | 0.91 | DPP4 (0.39) | DPP4ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL5597236 | 0.89 | DPP4 (0.40) | DPP4ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL12955580 | 0.88 | F2 (0.44) | DPP4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL9396036 | 0.88 | DPP4 (0.43) | DPP4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3239444 | 0.88 | F2 (0.46) | DPP4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL19210494 | 0.87 | ACE (0.44) | DPP4ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL10866479 | 0.86 | F2 (0.37) | DPP4ITGB3ITGA2BF2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132678-A1 | QUALITATIVE TEST FOR DIRECT ORAL ANTICOAGULANTS (DOACS) | F. HOFFMANN-LA ROCHE AG (CH) | 2025-06-26 | — | — | WO | claimed |
| CN-118516444-A | Reaction reagent for detecting prothrombin time by electrochemical method, test card and application | 杭州安旭生物科技股份有限公司 | 2024-08-20 | — | — | CN | claimed |
| EP-3955003-B1 | SENSORS FOR ASSAYING COAGULATION IN FLUID SAMPLES | ABBOTT POINT OF CARE INC (US) | 2023-06-21 | — | — | EP | claimed |
| EP-3198281-B1 | ELLAGIC ACID FORMULATIONS FOR USE IN COAGULATION ASSAYS | ABBOTT POINT OF CARE INC (US) | 2023-01-25 | — | — | EP | claimed |
| EP-3955003-A1 | SENSORS FOR ASSAYING COAGULATION IN FLUID SAMPLES | Abbott Point Of Care Inc (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2025132678-A1 | QUALITATIVE TEST FOR DIRECT ORAL ANTICOAGULANTS (DOACS) | F. HOFFMANN-LA ROCHE AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| CN-222866693-U | Test card for prothrombin time of blood sample, blood detection device and system | 杭州安旭生物科技股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-118516444-A | Reaction reagent for detecting prothrombin time by electrochemical method, test card and application | 杭州安旭生物科技股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-109507260-B | Electrochemical detection chip, electrochemical sensor, and preparation methods and applications thereof | 中国科学院苏州生物医学工程技术研究所 | 2024-07-05 | — | — | CN | disclosed |
| EP-3802550-B1 | NOVEL BENZIMIDAMIDES COMPOUNDS COMPRISING AN OXABORININ RING | INST NAT SANTE RECH MED (FR) | 2023-12-27 | — | — | EP | disclosed |
| US-11767333-B2 | Benzimidamides compounds comprising an oxaborinin ring | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-09-26 | — | — | US | disclosed |
| CN-112638532-B | Cartridge device with bypass channel for reducing fluid sample drift | 雅培医护站股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11352372-B2 | Benzimidamides compounds comprising an oxaborinin ring | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-06-07 | — | — | US | disclosed |
| EP-3198272-B1 | CARTRIDGE DEVICE IDENTIFICATION FOR COAGULATION ASSAYS IN FLUID SAMPLES | ABBOTT POINT OF CARE INC (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3955003-A1 | SENSORS FOR ASSAYING COAGULATION IN FLUID SAMPLES | Abbott Point Of Care Inc (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3954457-A2 | MICROFABRICATED DEVICE WITH MICRO-ENVIRONMENT SENSORS FOR ASSAYING COAGULATION IN FLUID SAMPLES | Abbott Point Of Care Inc (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-2451467-A1 | RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS) | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011086172-A1 | RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-07-21 | — | — | WO | disclosed |
| EP-1802649-B1 | SOLID PHASE PEPTIDE SYTHESIS | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7507791-B2 | Solid phase peptide synthesis of tri-peptide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352372-B2 | Benzimidamides compounds comprising an oxaborinin ring | KLKB1, KLK1, KLK5 | DPP4 773/4885ITGB3 2212/4885ITGA2B 2400/4885 |
| US-11767333-B2 | Benzimidamides compounds comprising an oxaborinin ring | KLKB1, KLK1, KLK2 | DPP4 790/4885ITGB3 2254/4885ITGA2B 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.